These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38543155)

  • 1. Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models.
    Zhang L; Feng F; Wang X; Liang H; Yao X; Liu D
    Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
    Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
    Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach.
    Ge YX; Zhang Z; Yan JY; Ma ZC; Wang YG; Xiao CR; Zhuang XM; Gao Y
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
    Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
    Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
    Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions.
    Lee W; Kim MS; Kim J; Aoki Y; Sugiyama Y
    Drug Metab Dispos; 2023 Sep; 51(9):1145-1156. PubMed ID: 36914276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds.
    Mao J; Ma F; Yu J; Bruyn T; Ning M; Bowman C; Chen Y
    Biopharm Drug Dispos; 2023 Aug; 44(4):315-334. PubMed ID: 37160730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
    Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
    Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug.
    Yang M; Wang AQ; Padilha EC; Shah P; Hagen NR; Ryu C; Shamim K; Huang W; Xu X
    Front Pharmacol; 2023; 14():1099425. PubMed ID: 37113753
    [No Abstract]   [Full Text] [Related]  

  • 16. In Vivo Hypoglycemic Studies of Polyherbal Phytoceuticals, Their Pharmacokinetic Studies and Dose Extrapolation by Allometric Scaling.
    De B; Bhandari K; Katakam P; Mitra A
    Curr Drug Discov Technol; 2017; 14(4):277-292. PubMed ID: 28359233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
    Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
    Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
    Gao ZW; Zhu YT; Yu MM; Zan B; Liu J; Zhang YF; Chen XY; Li XN; Zhong DF
    Acta Pharmacol Sin; 2015 Dec; 36(12):1528-36. PubMed ID: 26592518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of
    Li X; Chen C; Ding N; Zhang T; Zheng P; Yang M
    Front Pharmacol; 2022; 13():1073535. PubMed ID: 36588682
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
    Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
    Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.